Gene signatures in the management of hepatocellular carcinoma

Yujin Hoshida, Agrin Moeini, Clara Alsinet, Kensuke Kojima, Augusto Villanueva

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Clinical management of hepatocellular carcinoma (HCC) is a complex process. Currently existing prognostic staging systems have substantially improved the clinical outcome of patients by guiding treatment decision and allocation of medical resources. However, there is still room to refine many aspects of the framework based on more precise clinical outcome prediction and understanding of HCC molecular pathogenesis. Recent development of genomic technologies has enabled survey of molecular aberrations and deregulations directly from patient specimens in a comprehensive manner. This also has provided clues to therapeutic/preventive targets that could also serve as prognostic/predictive biomarkers. Structural alterations and chemical modifications of genomic DNA have been shown to be useful to guide molecular targeted therapies in some cancers. Gene expression signatures also hold promise as a way to probe functional biological status of the tumor specimen. However, accumulated studies have revealed roadblocks toward the goal to utilize the information in clinic. In this review, we discuss the gene signature's potential application, its pros and cons as a clinical test, technical issues in assay development, and strategies for clinical deployment in the context of HCC management. Recent updates of HCC gene signatures as well as emerging alternative modalities are also overviewed.

Original languageEnglish (US)
Pages (from-to)473-485
Number of pages13
JournalSeminars in oncology
Volume39
Issue number4
DOIs
StatePublished - Aug 1 2012
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Genes
Molecular Targeted Therapy
Resource Allocation
Transcriptome
Neoplasms
Biomarkers
Technology
DNA
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Gene signatures in the management of hepatocellular carcinoma. / Hoshida, Yujin; Moeini, Agrin; Alsinet, Clara; Kojima, Kensuke; Villanueva, Augusto.

In: Seminars in oncology, Vol. 39, No. 4, 01.08.2012, p. 473-485.

Research output: Contribution to journalArticle

Hoshida, Yujin ; Moeini, Agrin ; Alsinet, Clara ; Kojima, Kensuke ; Villanueva, Augusto. / Gene signatures in the management of hepatocellular carcinoma. In: Seminars in oncology. 2012 ; Vol. 39, No. 4. pp. 473-485.
@article{efbbd447793d44a798640bbd433277a4,
title = "Gene signatures in the management of hepatocellular carcinoma",
abstract = "Clinical management of hepatocellular carcinoma (HCC) is a complex process. Currently existing prognostic staging systems have substantially improved the clinical outcome of patients by guiding treatment decision and allocation of medical resources. However, there is still room to refine many aspects of the framework based on more precise clinical outcome prediction and understanding of HCC molecular pathogenesis. Recent development of genomic technologies has enabled survey of molecular aberrations and deregulations directly from patient specimens in a comprehensive manner. This also has provided clues to therapeutic/preventive targets that could also serve as prognostic/predictive biomarkers. Structural alterations and chemical modifications of genomic DNA have been shown to be useful to guide molecular targeted therapies in some cancers. Gene expression signatures also hold promise as a way to probe functional biological status of the tumor specimen. However, accumulated studies have revealed roadblocks toward the goal to utilize the information in clinic. In this review, we discuss the gene signature's potential application, its pros and cons as a clinical test, technical issues in assay development, and strategies for clinical deployment in the context of HCC management. Recent updates of HCC gene signatures as well as emerging alternative modalities are also overviewed.",
author = "Yujin Hoshida and Agrin Moeini and Clara Alsinet and Kensuke Kojima and Augusto Villanueva",
year = "2012",
month = "8",
day = "1",
doi = "10.1053/j.seminoncol.2012.05.003",
language = "English (US)",
volume = "39",
pages = "473--485",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Gene signatures in the management of hepatocellular carcinoma

AU - Hoshida, Yujin

AU - Moeini, Agrin

AU - Alsinet, Clara

AU - Kojima, Kensuke

AU - Villanueva, Augusto

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Clinical management of hepatocellular carcinoma (HCC) is a complex process. Currently existing prognostic staging systems have substantially improved the clinical outcome of patients by guiding treatment decision and allocation of medical resources. However, there is still room to refine many aspects of the framework based on more precise clinical outcome prediction and understanding of HCC molecular pathogenesis. Recent development of genomic technologies has enabled survey of molecular aberrations and deregulations directly from patient specimens in a comprehensive manner. This also has provided clues to therapeutic/preventive targets that could also serve as prognostic/predictive biomarkers. Structural alterations and chemical modifications of genomic DNA have been shown to be useful to guide molecular targeted therapies in some cancers. Gene expression signatures also hold promise as a way to probe functional biological status of the tumor specimen. However, accumulated studies have revealed roadblocks toward the goal to utilize the information in clinic. In this review, we discuss the gene signature's potential application, its pros and cons as a clinical test, technical issues in assay development, and strategies for clinical deployment in the context of HCC management. Recent updates of HCC gene signatures as well as emerging alternative modalities are also overviewed.

AB - Clinical management of hepatocellular carcinoma (HCC) is a complex process. Currently existing prognostic staging systems have substantially improved the clinical outcome of patients by guiding treatment decision and allocation of medical resources. However, there is still room to refine many aspects of the framework based on more precise clinical outcome prediction and understanding of HCC molecular pathogenesis. Recent development of genomic technologies has enabled survey of molecular aberrations and deregulations directly from patient specimens in a comprehensive manner. This also has provided clues to therapeutic/preventive targets that could also serve as prognostic/predictive biomarkers. Structural alterations and chemical modifications of genomic DNA have been shown to be useful to guide molecular targeted therapies in some cancers. Gene expression signatures also hold promise as a way to probe functional biological status of the tumor specimen. However, accumulated studies have revealed roadblocks toward the goal to utilize the information in clinic. In this review, we discuss the gene signature's potential application, its pros and cons as a clinical test, technical issues in assay development, and strategies for clinical deployment in the context of HCC management. Recent updates of HCC gene signatures as well as emerging alternative modalities are also overviewed.

UR - http://www.scopus.com/inward/record.url?scp=84864455290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864455290&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2012.05.003

DO - 10.1053/j.seminoncol.2012.05.003

M3 - Article

C2 - 22846864

AN - SCOPUS:84864455290

VL - 39

SP - 473

EP - 485

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4

ER -